OncoMatch/Clinical Trials/NCT05986318
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
Is NCT05986318 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Dexamethasone Oral for lung cancer.
Treatment: Dexamethasone Oral — In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: lung radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify